Prospective Grant of Exclusive License: Diagnostics of Fungal Infections, 33905 [05-11512]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 111 / Friday, June 10, 2005 / Notices
Thursday, May 12, 2005, Volume 70,
Number 91, pages 25075–25079.
The notice is amended as follows:
Page 25076, first column, Letter of
Intent Deadline, delete June 13, 2005,
and replace with August 15, 2005. Page
25076, first column, Application
Deadline, delete June 27, 2005, and
replace with August 31, 2005. Page
25076, third column, Fiscal Year Funds,
delete 2005, and replace with 2006.
Page 25076, third column, Anticipated
Award Date, delete August 31, 2005,
and replace with November 30, 2005.
Page 25077, third column, LOI Deadline
Date, delete June 13, 2005, and replace
with August 15, 2005. Page 25077, third
column, Application Deadline Date,
delete June 27, 2005, and replace with
August 31, 2005. Page 25079, first
column, Award Date, delete August 31,
2005, and replace with November 30,
2005.
Dated: June 2, 2005.
William P. Nichols,
Director, Procurement and Grants Office,
Centers for Disease Control and Prevention.
[FR Doc. 05–11524 Filed 6–9–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Prospective Grant of Exclusive
License: Diagnostics of Fungal
Infections
Technology Transfer Office,
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services.
ACTION: Notice.
AGENCY:
SUMMARY: This is a notice in accordance
with 35 U.S.C. 209(e) and 37 CFR
404.7(a)(1)(i) that the Centers for Disease
Control and Prevention (CDC),
Technology Transfer Office, Department
of Health and Human Services (DHHS),
is contemplating the grant of a
worldwide, limited field of use,
exclusive license to practice the
inventions embodied in the patent
application referred to below to
AerovectRx (AVRX), Corporation having
a place of business in Norcross, Georgia.
The patent rights in these inventions
have been assigned to the government of
the United States of America. The
patent applications to be licensed are:
PCT/US02/7973 entitled ‘‘Systems and
Methods for Aerosol Delivery of Agents,’’
filed 03.13.2002; and,
PCT/US03/019684 entitled ‘‘Mixing Vial,’’
filed 06.20.2003.
VerDate jul<14>2003
17:22 Jun 09, 2005
Jkt 205001
Status: Pending.
Issue Date: N/A.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7.
Technology: This technology adds a
new way to deliver vaccines,
specifically in mass immunization
campaigns.
Requests for a copy of this
patent application, inquiries, comments,
and other materials relating to the
contemplated license should be directed
to Andrew Watkins, Director,
Technology Transfer Office, Centers for
Disease Control and Prevention (CDC),
4770 Buford Highway, Mailstop K–79,
Atlanta, GA 30341, telephone: (770)
488–8610; facsimile: (770) 488–8615.
Applications for a license filed in
response to this notice will be treated as
objections to the grant of the
contemplated license. Only written
comments and/or applications for a
license which are received by CDC
within sixty days of this notice will be
considered. Comments and objections
submitted in response to this notice will
not be made available for public
inspection, and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552. A Signed Confidential Disclosure
Agreement (available under Forms at
https://www.cdc.gov/tto) will be required
to receive a copy of any pending patent
application.
ADDRESSES:
Dated: June 1, 2005.
James D. Seligman
Associate Director for Program Services,
Centers for Disease Control and Prevention.
[FR Doc. 05–11512 Filed 6–9–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
[Program Announce No. ‘‘HHS–2005–ACF–
OCS–EI–0053; CFDA 93.602]
Office of Community Services
Announcement for Assets for
Independence Program Grants
Office of Community Services
(OCS), Administration for Children and
Families, U.S. Department of Health and
Human Services.
ACTION: Notice of availability.
AGENCY:
Notice of an amendment to the
announcement published on February 9,
2005, concerning the application
process for Assets for Independence
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
33905
Program grants. This document
announces an additional closing date of
July 15, 2005. It also announces two
informational telephone conference
calls about the Assets for Independence
Program and the process for submitting
a grant proposal.
The program announcement
concerning the application process for
Assets for Independence Program grants
published on February 9, 2005 in
Volume 70, Federal Register, pages
6879–6888 is hereby modified. The
announcement is modified by adding
one additional application due date of
July 15, 2005, and a notification of two
informational telephone conference
calls concerning the Assets for
Independence Program and the process
for submitting a grant proposal.
SUMMARY: On February 9, 2005, the
Office of Community Services,
Administration for Children and
Families, U.S. Department of Health and
Human Services published an
announcement seeking applications for
the Assets for Independence Program.
The announcement appeared in Volume
70, pages 6879–6888 of the Federal
Register. This document announces one
additional application due date of July
15, 2005, which is in addition to the
three due dates listed in the February 9
standing announcement (March 15, June
15 and November 1). To be considered
timely for this additional due date only,
applications must be received at the
OCS Operations Center by July 15. (For
more details, see submission dates and
times section below.)
This document also announces two
informational telephone conference
calls concerning the Assets for
Independence Program and the process
for submitting a grant application.
Submission Dates and Times: The
new additional closing date for the
Assets for Independence Program is July
15, 2005. (This closing date is in
addition to three other valid closing
dates—March 15, June 15 and
November 1—as noted in the current
standing announcement.) Applications
received after 4:30 p.m. eastern time on
the July 15 closing date will be
classified as late, and will not be
reviewed this cycle.
Deadline: Applications shall be
considered as meeting an announced
deadline if they are received on or
before the due date. Applicants are
responsible for ensuring applications
are mailed or submitted electronically
well in advance of the application due
date.
Applications hand carried by
applicants, applicant couriers, other
representatives of the applicant, or by
overnight/express mail couriers shall be
E:\FR\FM\10JNN1.SGM
10JNN1
]]>Agencies
[Federal Register Volume 70, Number 111 (Friday, June 10, 2005)]
[Notices]
[Page 33905]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-11512]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Prospective Grant of Exclusive License: Diagnostics of Fungal
Infections
AGENCY: Technology Transfer Office, Centers for Disease Control and
Prevention (CDC), Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention
(CDC), Technology Transfer Office, Department of Health and Human
Services (DHHS), is contemplating the grant of a worldwide, limited
field of use, exclusive license to practice the inventions embodied in
the patent application referred to below to AerovectRx (AVRX),
Corporation having a place of business in Norcross, Georgia. The patent
rights in these inventions have been assigned to the government of the
United States of America. The patent applications to be licensed are:
PCT/US02/7973 entitled ``Systems and Methods for Aerosol Delivery of
Agents,'' filed 03.13.2002; and,
PCT/US03/019684 entitled ``Mixing Vial,'' filed 06.20.2003.
Status: Pending.
Issue Date: N/A.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
Technology: This technology adds a new way to deliver vaccines,
specifically in mass immunization campaigns.
ADDRESSES: Requests for a copy of this patent application, inquiries,
comments, and other materials relating to the contemplated license
should be directed to Andrew Watkins, Director, Technology Transfer
Office, Centers for Disease Control and Prevention (CDC), 4770 Buford
Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610;
facsimile: (770) 488-8615. Applications for a license filed in response
to this notice will be treated as objections to the grant of the
contemplated license. Only written comments and/or applications for a
license which are received by CDC within sixty days of this notice will
be considered. Comments and objections submitted in response to this
notice will not be made available for public inspection, and, to the
extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552. A Signed Confidential Disclosure
Agreement (available under Forms at https://www.cdc.gov/tto) will be
required to receive a copy of any pending patent application.
Dated: June 1, 2005.
James D. Seligman
Associate Director for Program Services, Centers for Disease Control
and Prevention.
[FR Doc. 05-11512 Filed 6-9-05; 8:45 am]
BILLING CODE 4163-18-P
